Eli Lilly's retatrutide just produced the strongest weight loss data ever seen in a Phase 3 obesity trial. On December 11, 2025, Lilly announced topline results from TRIUMPH-4 showing participants on the 12 mg dose lost an average of 28.7% of their body weight — 71.2 pounds — over 68 weeks. The drug also slashed knee osteoarthritis pain by 75%, improved cardiovascular risk markers, and reduced systolic blood pressure by 14 mmHg.
These results mark the first successful Phase 3 readout for retatrutide, and seven more trials are expected to report data throughout 2026. If the remaining TRIUMPH program delivers, Lilly could file for FDA approval by late 2026, with a potential approval in 2027.
Here's a breakdown of everything we know so far.
What Is Retatrutide?
Retatrutide (LY3437943) is a once-weekly injectable peptide that activates three metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple-agonist mechanism distinguishes it from every other obesity drug on the market or in late-stage development.
For context, semaglutide (Wegovy/Ozempic) targets GLP-1 alone. Tirzepatide (Zepbound/Mounjaro) targets GLP-1 and GIP. Retatrutide adds the glucagon receptor — and that third pathway appears to be what pushes weight loss into territory no other drug has reached.
Each receptor contributes distinct metabolic effects:
- GLP-1 receptor: Suppresses appetite, slows gastric emptying, stimulates insulin secretion, and reduces food intake through central nervous system signaling.
- GIP receptor: Works synergistically with GLP-1 to enhance insulin release and may improve fat metabolism. GIP receptor activation appears to amplify the appetite-suppressing effects of GLP-1.
- Glucagon receptor: Increases energy expenditure, promotes lipolysis (fat breakdown), reduces lipogenesis (fat storage), and may stimulate thermogenesis through effects on brown adipose tissue. This is the key differentiator — glucagon activation drives caloric expenditure in addition to reduced intake.
The molecule itself is a 39-amino acid peptide linked to a C20 fatty diacid moiety that extends its half-life for once-weekly dosing.
TRIUMPH-4: The First Phase 3 Win
The TRIUMPH-4 trial enrolled 445 adults with obesity (BMI 30+) or overweight (BMI 27+) who also had moderate-to-severe knee osteoarthritis. Participants were randomized 1:1:1 to receive retatrutide 9 mg, retatrutide 12 mg, or placebo via once-weekly subcutaneous injection for 68 weeks. Dosing started at 2 mg and escalated every 4 weeks.
Weight Loss Results
| Metric | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Mean weight loss (%) | 26.4% | 28.7% | 2.1% |
| Mean weight loss (kg) | 29.1 kg (64.2 lbs) | 32.3 kg (71.2 lbs) | 2.1 kg (4.6 lbs) |
| Achieved >= 25% loss | 47.7% | 58.6% | 1.3% |
| Achieved >= 30% loss | 30.5% | 39.4% | 0.8% |
| Achieved >= 35% loss | 18.2% | 23.7% | 0.0% |
Average baseline weight was 112.7 kg (248.5 lbs) with a mean BMI of 40.4 kg/m². Over 84% of participants had a baseline BMI of 35 or higher.
Nearly 1 in 4 participants on the 12 mg dose lost more than 35% of their body weight. That level of weight reduction has historically only been achievable through bariatric surgery.
Knee Osteoarthritis Pain Relief
TRIUMPH-4 was specifically designed to test retatrutide in patients with obesity-related knee osteoarthritis, making it the first obesity drug trial to use joint pain as a primary endpoint alongside weight loss.
| Metric | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| WOMAC pain reduction (points) | 4.5 | 4.4 | 2.4 |
| WOMAC pain reduction (%) | 75.8% | 74.3% | 40.3% |
| Physical function improvement (points) | 4.1 | 4.2 | — |
| Physical function improvement (%) | 71.8% | 73.7% | — |
| Pain-free at end of trial | 14.1% | 12.0% | 4.2% |
The pain reduction is noteworthy in competitive context. By comparison, semaglutide achieved approximately 42% pain reduction in prior knee OA trials. Retatrutide's ~75% pain reduction nearly doubles that benchmark.
Cardiovascular Improvements
Beyond weight loss and pain relief, retatrutide demonstrated meaningful improvements across cardiovascular risk markers:
- Systolic blood pressure: Reduced by 14.0 mmHg on the 12 mg dose
- Non-HDL cholesterol: Significant reductions at both doses
- Triglycerides: Significant reductions at both doses
- hs-CRP (high-sensitivity C-reactive protein): Significant reductions, indicating reduced systemic inflammation
These findings are consistent with what was seen in the Phase 2 trial and suggest retatrutide's metabolic benefits extend well beyond the scale.
Safety Profile: What to Watch
Retatrutide's safety profile in TRIUMPH-4 was broadly consistent with other incretin-based therapies — with one notable exception.
Common Side Effects
| Adverse Event | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Nausea | 38.1% | 43.2% | 10.7% |
| Diarrhea | 34.7% | 33.1% | 13.4% |
| Constipation | 21.8% | 25.0% | 8.7% |
| Vomiting | 20.4% | 20.9% | 0.0% |
| Dysesthesia | 8.8% | 20.9% | 0.7% |
Gastrointestinal side effects (nausea, diarrhea, constipation, vomiting) are the expected class effects of GLP-1-based drugs and were dose-dependent. Most GI events were mild to moderate and concentrated during the dose-escalation phase. They infrequently led to treatment discontinuation.
The Dysesthesia Signal
The most closely watched finding is dysesthesia — an abnormal sensation of touch, often described as tingling, numbness, or burning. In TRIUMPH-4, dysesthesia occurred in 8.8% of the 9 mg group and 20.9% of the 12 mg group, versus just 0.7% in placebo. This side effect was not observed at meaningful rates in the Phase 2 trial, which surprised analysts who had expected a consistent safety profile.
This is a new signal that wasn't anticipated. At the 12 mg dose, roughly 1 in 5 participants reported it. While the events were not described as severe enough to drive significant discontinuation on their own, the dose-dependent pattern and the 20.9% incidence at the highest dose will be a focus of scrutiny as additional TRIUMPH data arrives. The upcoming trials will be critical for understanding whether dysesthesia is manageable, dose-related, or a limiting factor.
Discontinuation Rates
Treatment discontinuation due to adverse events was 12.2% at 9 mg and 18.2% at 12 mg, compared to 4.0% for placebo. Analysts described these rates as "overall acceptable" for an obesity drug delivering this magnitude of efficacy, though some discontinuations were attributed to "perceived excessive weight loss" — a notable finding suggesting dose optimization and maintenance strategies will be important.
The Full TRIUMPH Program
TRIUMPH-4 is just the first of eight Phase 3 trials in the retatrutide registrational program. Lilly launched TRIUMPH in 2023, enrolling approximately 5,800 participants across the entire program. Seven additional trials are expected to read out in 2026, covering a broad range of obesity-related conditions:
| Trial | Condition | Expected |
|---|---|---|
| TRIUMPH-1 | Obesity (general population) | 2026 |
| TRIUMPH-2 | Type 2 diabetes | 2026 |
| TRIUMPH-3 | Obesity (maintenance dosing) | 2026 |
| TRIUMPH-4 | Obesity + knee osteoarthritis | Completed (Dec 2025) |
| TRIUMPH-5 | Obstructive sleep apnea | 2026 |
| TRIUMPH-6 | Chronic low back pain | 2026 |
| TRIUMPH-7 | Metabolic dysfunction-associated steatotic liver disease (MASLD) | 2026 |
| TRIUMPH-8 | Cardiometabolic outcomes | 2026 |
TRIUMPH-3 is particularly significant because it will include a 4 mg maintenance dose alongside the 9 mg and 12 mg treatment doses. If a lower maintenance dose can preserve weight loss with fewer side effects, it would address the dysesthesia concern and the "excessive weight loss" discontinuations seen in TRIUMPH-4.
How Retatrutide Compares
The obesity drug landscape has evolved rapidly. Here's where retatrutide fits:
| Drug | Developer | Mechanism | Best Phase 3 Weight Loss | Status |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | GLP-1 + GIP + Glucagon | 28.7% (TRIUMPH-4) | Phase 3 |
| Tirzepatide (Zepbound) | Eli Lilly | GLP-1 + GIP | 22.5% (SURMOUNT-1) | FDA-approved |
| Semaglutide (Wegovy) | Novo Nordisk | GLP-1 | 16.9% (STEP 1) | FDA-approved |
| CagriSema | Novo Nordisk | GLP-1 + Amylin | 22.7% (REDEFINE 1) | Pending FDA |
| Survodutide | Boehringer/Zealand | GLP-1 + Glucagon | 18.7% (Phase 2) | Phase 3 |
Retatrutide's 28.7% represents the highest average weight loss ever achieved in a registrational-quality obesity trial. The addition of the glucagon receptor — the "third agonist" — appears to meaningfully extend efficacy beyond what dual agonists like tirzepatide can deliver.
FDA Approval Timeline
Based on currently available information:
- Phase 3 completion: Seven remaining TRIUMPH trials expected to report throughout 2026
- NDA filing: Expected late 2026 (contingent on favorable TRIUMPH results)
- FDA review: Standard review timeline of 6-10 months from filing
- Potential approval: First or second quarter of 2027
GlobalData projects retatrutide could reach $15.6 billion in annual sales by 2031. BMO Capital Markets called the TRIUMPH-4 results "the strongest efficacy reported to date" and noted they solidify retatrutide's position as a next-generation asset in Lilly's weight loss portfolio.
What This Means for the Research Community
Retatrutide represents a meaningful step forward for several reasons:
For weight loss: The 28.7% average weight loss — with nearly 1 in 4 participants losing more than 35% — moves pharmacological weight management closer to bariatric surgery outcomes. This challenges the assumption that drugs can only deliver incremental improvements.
For comorbidity treatment: TRIUMPH-4 proved that a single molecule can simultaneously address obesity and a major comorbidity (knee OA) with clinically meaningful results in both endpoints. The remaining trials targeting sleep apnea, liver disease, diabetes, and cardiovascular outcomes could extend this pattern.
For mechanism design: The triple-agonist approach validates the hypothesis that adding the glucagon receptor to GLP-1/GIP signaling provides additive metabolic benefits. This opens the door for additional multi-receptor peptide designs.
For the ongoing dysesthesia question: The emergence of this new side effect signal — absent in Phase 2 — underscores why large Phase 3 programs exist. The remaining TRIUMPH readouts will determine whether this is a manageable nuisance or a meaningful barrier, particularly at the 12 mg dose.
What This Means for the Peptide Industry
Retatrutide's TRIUMPH-4 data doesn't just move the needle for Eli Lilly — it reshapes the trajectory of the entire peptide therapeutics industry.
The multi-receptor era is here. Semaglutide proved single-receptor GLP-1 agonists work. Tirzepatide proved dual-receptor agonists work better. Retatrutide now proves that triple-receptor agonists push efficacy further still. The implication is clear: the industry is moving toward increasingly sophisticated multi-target peptide designs. Companies already exploring quad-receptor agonists and combination peptide therapies will be emboldened by these results. Expect a wave of pipeline investment into novel multi-receptor candidates across metabolic, cardiovascular, and inflammatory disease areas.
Peptides are becoming primary therapies, not adjuncts. Historically, peptide-based drugs were positioned as secondary treatments — add-ons to lifestyle modification or surgical alternatives for edge cases. Retatrutide's 28.7% weight loss, combined with its cardiovascular and joint benefits, positions it as a potential first-line intervention for obesity and its comorbidities. This elevates peptides from niche specialty drugs to mainstream medicine, with implications for how insurers cover them, how physicians prescribe them, and how patients perceive them.
The compounding pharmacy landscape will shift. When retatrutide eventually reaches market, it will intensify demand for GLP-1-class peptides at the pharmacy level. The current supply constraints around semaglutide and tirzepatide have already fueled a massive compounding pharmacy boom. A third blockbuster in the category — with even stronger efficacy data — will deepen that trend. For the research peptide community, retatrutide's approval would further legitimize the class and could influence how regulators approach compounded peptide access more broadly.
Beyond obesity: the indication expansion playbook. TRIUMPH-4's dual-endpoint design (obesity + knee OA) is a strategic template the industry is watching closely. If single molecules can address obesity alongside sleep apnea, liver disease, chronic pain, and cardiovascular risk — as the remaining TRIUMPH trials aim to prove — it rewrites the commercial model for peptide therapeutics. Rather than developing narrow, single-indication drugs, companies will design broad-spectrum peptides tested across multiple conditions simultaneously. This approach maximizes both clinical impact and market size.
Research peptide interest will surge. Every major clinical milestone for GLP-1-class drugs has driven increased interest in the broader peptide research space. Retatrutide's results will accelerate this trend. Researchers, clinicians, and patients who enter the space through metabolic peptides often expand into adjacent categories — tissue repair, cognitive enhancement, immune modulation, longevity. The rising tide of peptide awareness lifts all boats, and retatrutide may be the largest wave yet.
What to Watch in 2026
The next 12 months will be decisive for retatrutide:
- TRIUMPH-1 results — The general obesity trial is the core registrational study. Its results will likely form the basis of Lilly's FDA filing.
- TRIUMPH-3 maintenance data — The 4 mg maintenance dose results will clarify whether patients can step down to a lower dose after initial weight loss, potentially reducing side effect burden.
- Dysesthesia tracking — Whether the tingling/numbness signal replicates across other TRIUMPH trials, and at what rates, will be critical for the risk-benefit assessment.
- Competitive readouts — Novo Nordisk's CagriSema is also advancing. The obesity drug market is rapidly evolving, and late 2026 will reveal how these next-generation compounds stack up.
This article will be updated as additional TRIUMPH Phase 3 data becomes available throughout 2026.
PeptideWiki provides educational information about research peptides. This content is not medical advice. Always consult with a qualified healthcare provider before beginning any peptide protocol. See our full disclaimer for details.
